Ucb, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$65Mgeneral payments (2019-2025)

$1.4Mresearch payments (2019-2025)

55,291clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $5.2M

2020 $2.8M

2021 $4.6M

2022 $5.9M

2023 $7.8M

2024 $17M

2025 $22M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Dermatology $19M

Rheumatology $12M

Neurology (Psychiatry & Neurology) $10M

Physician Assistant $4.1M

Neurology With Special Qualifications In Child Neurology $2.4M

Epilepsy $1.7M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

Clinician	Location	Specialty	General payments (2019-2025)
David Burdette	Grand Rapids, MI	Epilepsy	$615,384.30
Sergio Schwartzman	New York, NY	Rheumatology	$489,561.52
Firas Hougeir	Douglasville, GA	Dermatology	$470,958.90
Kimberly Vincent	Nashville, TN		$458,930.96
Kristi Hawley	Caledonia, MI	Dermatology	$447,828.74
Ein Gun Song	Mill Creek, WA	Mohs-Micrographic Surgery	$393,432.83
Grace Wright	New York, NY	Rheumatology	$383,369.28
Ahmad Amin	Naperville, IL	Dermatology	$379,337.97
Mounzer Yassin Kassab	East Lansing, MI	Vascular Neurology	$369,838.86
Selim Benbadis	Tampa, FL	Neurology (Psychiatry & Neurology)	$365,425.25

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.